



Published in final edited form as:

Pediatr Res. 2009 April ; 65(4): 437–442. doi:10.1203/PDR.0b013e3181994fa0.

Preclinical Neonatal Rat Studies of Heparin-Binding EGF-Like Growth Factor in Protection of the Intestines From Necrotizing Enterocolitis

ANDREI RADULESCU, NICHOLAS A. ZORKO, XIAOYI YU, and GAIL E. BESNER

Center for Perinatal Research [A.R., X.Y., G.E.B.], Department of Pediatric Surgery [G.E.B.], Nationwide Children's Hospital, Columbus, Ohio, 43205; College of Medicine [N.A.Z., G.E.B.], The Ohio State University, Columbus, Ohio 43210

Abstract

We have previously demonstrated that enterally administered heparin-binding EGF-like growth factor (HB-EGF) produced in *Escherichia coli* decreases the incidence and severity of intestinal injury in a neonatal rat model of necrotizing enterocolitis (NEC). In preparation for upcoming human clinical trials, large-scale production of HB-EGF according to Good Manufacturing Practice (GMP) has been successfully accomplished using a *Pichia pastoris* yeast system. The current studies used a neonatal rat model of NEC to elucidate several important preclinical characteristics of HB-EGF therapy. We found that enteral administration of HB-EGF (800 $\mu\text{g}/\text{kg}$ /dose) four times a day effectively reduced the incidence and severity of NEC, that *Pichia*-derived HB-EGF was not significantly different from *E. coli*-derived HB-EGF in preventing NEC, that EGF was not superior to HB-EGF in preventing NEC, and that prophylactic administration of HB-EGF added to formula starting with the first feed or 12 h later significantly reduced the incidence of NEC, with no change in the incidence of NEC noted if HB-EGF was added to the formula starting 24, 48, or 72 h after birth. Thus, large-scale production of GMP-grade HB-EGF in *Pichia pastoris* yeast produces a biologically active molecule suitable for human clinical trials.

Necrotizing enterocolitis (NEC) is the most common gastrointestinal emergency in premature newborn infants (1,2). With aggressive management leading to the salvage of premature infants from the pulmonary standpoint, the incidence of NEC is increasing, and is expected to soon replace pulmonary insufficiency as the leading cause of death in premature infants (3). NEC mortality ranges from 20 to 50%, resulting in over 1000 deaths in this country each year. Survivors frequently develop malabsorption, malnutrition, total parenteral nutrition-related complications, intestinal strictures, and short bowel syndrome (4).

Because prematurity is the single most important risk factor for NEC, it is possible that absent or reduced levels of specific factors that are normally expressed during later periods of gestation may contribute to the development of this condition. We have previously examined HB-EGF mRNA expression in intestine resected from patients with NEC, comparing intestinal samples from areas afflicted with acute NEC with the more normal intestine at the resection margins. We found that NEC-afflicted intestine had significantly lower HB-EGF mRNA levels compared with intestine at the resection margins (5). We speculated that a relative deficiency of HB-EGF in the NEC-afflicted intestine might reflect

part of the pathogenesis of NEC. With this in mind, exogenous replacement of HBEGF may be clinically valuable as a means to reduce the incidence of NEC. Although many potential preventive strategies for NEC have been examined in the past, none have led to consistently positive therapeutic results (5). Presently, no clinical trials have addressed the use of growth factors as intestinal cytoprotective agents for NEC.

Heparin-binding EGF-like growth factor (HB-EGF) was initially identified in the conditioned medium of cultured human macrophages (6) and later found to be a member of the EGF family of growth factors (7). HB-EGF exerts its mitogenic effects by binding and activation of EGF receptor subtypes ErbB-1 and ErbB-4 (8). In addition, HB-EGF exerts chemotactic effects when binding to the HB-EGF-specific receptor N-arginine dibasic convertase (NrdC) (9). Importantly, endogenous HB-EGF is protective in various pathologic conditions and plays a pivotal role in mediating the earliest cellular responses to proliferative stimuli and cellular injury.

We have previously demonstrated that enteral administration of *Escherichia coli*-derived HB-EGF decreases the incidence and severity of intestinal injury in a neonatal rat model of NEC, with the greatest protective effects found at doses of 600 or 800 $\mu\text{g}/\text{kg}/\text{dose}$ (10). We have also reported that HB-EGF protects the intestines from injury after intestinal ischemia/reperfusion (11) or hemorrhagic shock and resuscitation (12). Given the evidence to date demonstrating its intestinal protective effects, HB-EGF may represent a promising therapeutic strategy for intestinal diseases including NEC. In preparation for upcoming human clinical trials of HB-EGF for the prevention of NEC, we have produced human recombinant mature HB-EGF according to Good Manufacturing Process (GMP) using a high-yield *Pichia pastoris* yeast expression system. The goals of the current project were to determine the optimal HB-EGF dosing interval, to examine the efficacy of *Pichia*-derived GMP-grade HB-EGF compared with *E. coli*-derived HB-EGF, to evaluate the efficacy of HB-EGF and EGF in preventing NEC, and to compare prophylactic and therapeutic administration of HB-EGF in the prevention of NEC.

MATERIALS AND METHODS

Neonatal rat model of experimental necrotizing enterocolitis

The experimental protocol was performed according to the guidelines for the ethical treatment of experimental animals and approved by our Institutional Animal Care and Use Committee (#04203AR). NEC was induced using a modification of the model described by Barlow *et al.* (13). Pregnant time-dated Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN) were delivered by C-section under CO₂ anesthesia on day 21.5 of gestation. Newborn rats were placed in an incubator and fed *via* gavage with formula containing 15 g Similac 60/40 (Ross Pediatrics, Columbus, OH) in 75 mL Esbilac (Pet-Ag, New Hampshire, IL), providing 836.8 kJ/kg per day. Feeds were started at 0.1 mL every 4 h beginning 2 h after birth and advanced as tolerated up to a maximum of 0.4 mL per feeding by the fourth day of life. Animals were exposed to a single dose of intragastric lipopolysaccharide (LPS; 2 mg/kg) 8 h after birth, and were stressed by exposure to hypoxia (100% nitrogen for 1 min) followed by hypothermia (4°C for 10 min) twice a day beginning immediately after birth until the end of the experiment.

To investigate HB-EGF dosing interval, 203 rat pups were randomized to receive HB-EGF added to their feeds two (BID), three (TID), four (QID), or six (HID) equally spaced times a day. To compare the efficacy of *E. coli*-derived and *P. pastoris*-derived HB-EGF, 199 pups were randomized to receive 600, 800, or 1000 $\mu\text{g}/\text{kg}/\text{dose}$ of each type of HB-EGF added to their feeds QID or HID. To compare the efficacy of HB-EGF and EGF in the prevention of NEC, 120 pups were randomized to receive either equal mass doses of each growth factor

(HB-EGF 800 $\mu\text{g}/\text{kg}/\text{dose}$ versus EGF 800 $\mu\text{g}/\text{kg}/\text{dose}$) or molar equivalents of each growth factor (HB-EGF 800 $\mu\text{g}/\text{kg}/\text{dose}$ versus EGF 570 $\mu\text{g}/\text{kg}/\text{dose}$). To compare prophylactic and therapeutic administration of HB-EGF in NEC, 137 pups were exposed to stress beginning immediately after birth, with HB-EGF (800 $\mu\text{g}/\text{kg}/\text{dose}$) added to the feeds starting at 2, 12, 24, 48, or 72 h after birth.

The HB-EGF used in all experiments was GMP grade human mature HB-EGF produced in *P. pastoris* yeast and supplied to us by Trillium Therapeutics, Toronto, Canada. *E. coli*-derived recombinant human mature HB-EGF was produced in our laboratory as previously described (14). EGF was produced in *E. coli* and purchased from Vybion (Ithaca, NY). In all experiments, pups were euthanized on development of clinical signs of NEC (abdominal distention, bloody bowel movements, respiratory distress, lethargy). Remaining animals were killed 96 h after birth.

Histologic Injury Score

On sacrifice, the gastrointestinal tract was carefully removed and visually evaluated for signs of NEC (areas of bowel necrosis, intestinal hemorrhage, perforation). Three pieces of duodenum, jejunum, ileum, and colon from every animal were fixed in 10% formalin for 24 h, paraffin-embedded, sectioned at 5 μm thickness, and stained with hematoxylin and eosin for histologic evaluation of the presence and/or degree of NEC using the NEC histologic injury scoring system described by Caplan *et al.* (15). Histologic changes were graded as follows: grade 0, no damage; grade 1, epithelial cell lifting or separation; grade 2, sloughing of epithelial cells to the mid villus level; grade 3, necrosis of the entire villus; and grade 4, transmural necrosis. Tissues were graded blindly by two independent observers. Tissues with histologic scores of 2 or higher were considered positive for NEC (Fig. 1).

Statistical analyses

Fisher's exact test was used for comparing the incidence of NEC between groups with no adjustments made for multiple comparisons. *p*-values less than 0.05 were considered statistically significant. All statistical analyses were performed using SAS (version 9.1, SAS Institute, Cary, NC).

RESULTS

Dosing interval of HB-EGF administration

We have previously shown that enteral administration of HB-EGF at doses of 600 or 800 $\mu\text{g}/\text{kg}/\text{dose}$ administered HID significantly decreases the incidence and severity of experimental NEC (10). However, we did not examine whether administration less frequently than HID could also protect the intestines from NEC. In this experiment, we examined the effect of decreasing HB-EGF dosing intervals. Animals subjected to stress had a 63% incidence of NEC, with histopathologic changes ranging from moderate, mid-level villous necrosis (grade 2) to severe necrosis of the entire villous (grade 3 and 4) (Fig. 2A and B). Rat pups that received HB-EGF (800 $\mu\text{g}/\text{kg}/\text{dose}$) added to every feed (HID) showed a significant decrease in the incidence of NEC to 39% ($p = 0.03$). We found that decreasing the HB-EGF dosing interval to either BID or QID also significantly reduced the percent of animals that developed NEC to 38% and 22%, respectively ($p = 0.05$ and $p < 0.001$). There was no statistically significant difference between administration of HB-EGF HID or QID. Although there was a trend toward an increased number of animals with grade 2 NEC in the HID group, there were no statistically significant differences between QID and HID dosing when comparing animals with grade 2 NEC ($p = 0.24$).

In addition to decreasing the incidence of NEC, we also noted that addition of HB-EGF to the feeds decreased the degree of intestinal damage in the pups that did develop NEC. In non-HB-EGF-treated pups, of the 63% of pups that developed NEC, 1.7% had grade 4 injury, 24.1% had grade 3 injury, and 74.1% had grade 2 injury. However, in pups treated with HBEGF QID, of the 22% that did develop NEC, only 16.6% had grade 3 injury, and 83.3% had grade 2 injury. Furthermore, we found that ~15% of non-HB-EGF-treated animals survived the 96-h protocol without developing clinical signs of NEC, but with the addition of HB-EGF to the feeds QID or HID, survival significantly increased to ~80% (data not shown).

Comparison of *P. pastoris*-derived and *E. coli*-derived HB-EGF

We have produced recombinant GMP-grade HB-EGF in quantities sufficient for human clinical trials using a *P. pastoris* yeast expression system. We next tested the efficacy of *P. pastoris*-derived HB-EGF compared with *E. coli*-derived HB-EGF in preventing NEC. Because our previous studies of *E. coli*-derived HB-EGF in preventing NEC tested doses up to but not exceeding 800 $\mu\text{g}/\text{kg}/\text{dose}$, we also tested whether increasing the dose of HB-EGF to 1000 $\mu\text{g}/\text{kg}/\text{dose}$ would lead to further beneficial effects. In this experiment, the incidence of NEC in stressed pups was 68%. When tested at doses of 600, 800, or 1000 $\mu\text{g}/\text{kg}/\text{dose}$, and dosing intervals of QID or HID, there were no significant differences in efficacy between *E. coli*-derived and *Pichia*-derived HB-EGF (Fig. 3A and B). Although there was a trend toward a decreased incidence of NEC in animals that received *Pichia*-derived HB-EGF HID compared with QID, there were no statistically significant differences between the two groups at either of the three doses of HB-EGF tested.

Comparison of HB-EGF and EGF

To accurately compare the efficacy of HB-EGF and EGF in preventing NEC, we chose a dose of HB-EGF (800 $\mu\text{g}/\text{kg}/\text{dose}$) with proven efficacy in preventing NEC in our hands, and compared this dose to both the equivalent mass dose (800 $\mu\text{g}/\text{kg}/\text{dose}$) and the equivalent molar dose of EGF (570 $\mu\text{g}/\text{kg}/\text{dose}$). Comparing equal molar doses takes into account the different molecular masses of the mature forms of the two growth factors (*i.e.* HB-EGF residues 74–148; [74aa; Mr7400] versus EGF residues 1–53 [53aa; Mr 5300]), and adds an equal number of molecules of each growth factor to the experiment. In this experiment, animals subjected to stress had an incidence of NEC of 63.3% (Fig. 4A and B). HB-EGF (800 $\mu\text{g}/\text{kg}/\text{dose}$) significantly decreased the incidence of NEC to 30.7% ($p = 0.009$). The equivalent mass dose of EGF (800 $\mu\text{g}/\text{kg}/\text{dose}$) significantly decreased the incidence of NEC to 21.7% ($p = 0.002$), and the equivalent molar dose (570 $\mu\text{g}/\text{kg}/\text{dose}$) decreased the incidence to 40.9% ($p = 0.12$). There were no statistically significant differences in the incidence of NEC between HB-EGF and either of the two doses of EGF tested.

Comparison of prophylactic and therapeutic administration of HB-EGF

In the future, clinical administration of HB-EGF for NEC could be performed prophylactically in an attempt to prevent NEC from developing, or therapeutically in an attempt to reverse or inhibit the progression of NEC. We previously used a rodent model of intestinal ischemia/reperfusion injury secondary to superior mesenteric artery occlusion to show that HB-EGF can significantly protect the intestines from injury when administered either prophylactically or therapeutically; however, the best results were obtained when HB-EGF was administered before injury (16). Similar experiments using the rodent model of NEC have not been previously performed. We therefore subjected rat pups to stress beginning immediately after birth, with addition of HB-EGF (800 $\mu\text{g}/\text{kg}/\text{dose}$) to the feeds beginning with the first feed at 2 h after birth, or beginning after 12, 24, 48, or 72 h after birth. In this experiment, the incidence of NEC in stressed animals was 67.3% (Fig. 5). The

incidence of NEC decreased significantly to 26.3% when HB-EGF was added to the feeds starting at 2 h, and to 25.0% when HB-EGF was started 12 h after birth ($p = 0.003$ and $p = 0.001$, respectively). In addition to decreasing the incidence of NEC, we also noted that HB-EGF supplementation at the 2 h or 12 h time points decreased the degree of intestinal damage in the pups that did develop NEC. Of the 67.3% of stressed animals that developed NEC, 78.8% had grade 2 injury, and 21.2% had grade 3 injury. In animals that received HB-EGF starting 2 h after birth, of the 26.3% that went on to develop NEC, only 20% had grade 3 injury and 80% had grade 2 injury. In pups that received HB-EGF starting 12 h after birth, of the 25% that went on to develop NEC, none had grade 3 injury and 100% had grade 2 injury. When HB-EGF administration was started at later time points (24, 48, and 72 h), there were no significant differences in the incidence or severity of NEC compared with control animals.

We recently examined the time course for development of NEC in our NEC model, and have determined that clinical signs and intestinal histologic damage consistent with NEC are noted beginning at 48–72 h of stress (data not shown). Here we show that administration of HB-EGF starting at 2 or 12 h of stress significantly decreased the incidence of NEC, administration starting at 24 h of stress decreased the incidence of NEC to a lesser degree, and administration starting at 48 or 72 h of stress does not significantly decrease the incidence of NEC. This suggests that once intestinal necrosis has already occurred in these animals, HB-EGF is less effective in preventing NEC. Thus, these data suggest that prophylactic rather than therapeutic use of HB-EGF is more effective in this animal model.

DISCUSSION

Although many clinical trials have been conducted in an attempt to protect newborns from NEC, clinical trials of growth factors in the prevention of NEC have never been performed. We have used several different intestinal injury models to show that HB-EGF protects the intestines from injury (5,10–12). We have also shown that HB-EGF is present in human amniotic fluid and breast milk, ensuring continuous natural exposure of the fetal and newborn intestine to endogenous levels of the growth factor before and after birth (17). Supplementation of enteral feeds with a biologically active substance such as HB-EGF may represent a logical and safe way to reduce intestinal injury resulting in NEC. HB-EGF administration to very low birth weight patients (<1500 g) who are most at risk for developing NEC may facilitate maturation, enhance regenerative capacity, and increase resistance of the intestinal mucosa to injury.

We have previously shown that intragastric administration of ^{125}I -labeled HB-EGF to rats leads to delivery of the growth factor to the entire GI tract including the colon within 8 h (18). We found peak HB-EGF concentrations in the plasma 4 h after dosing, with a half-life in the absorption phase of 2.38 h and in the elimination phase of 11.13 h. As part of our extensive recent preclinical studies of HB-EGF, single-dose and repeat-dose toxicology studies have been performed in neonatal and adult Sprague Dawley rats and Yukatan minipigs. HB-EGF was administered enterally for up to 28 d, at doses up to 70 times higher than the doses effective in our rat NEC model. Even at the highest doses, there were no toxic or adverse effects detected, suggesting that there is an excellent safety margin for HB-EGF administration (unpublished data). In addition, there was no systemic absorption detected with enteral administration of HB-EGF, even at the highest doses administered. These findings collectively support the clinical feasibility and safety of enteral administration of HB-EGF in protection of the intestines from injury. The results reported here, involving HB-EGF dosage, dosing interval, and efficacy of GMP-grade HB-EGF, adds important preclinical information to the design of future clinical trials of HB-EGF in NEC.

EGF family members are of interest as intestinal protective agents because of their roles in gut maturation and function. Infants with NEC have decreased levels of salivary EGF, as do very premature infants (19,20). EGF preserves gut barrier function, increases intestinal enzyme activity, and improves nutrient transport (21). EGF receptor (EGFR) knockout mice develop epithelial cell abnormalities and hemorrhagic necrosis of the intestine similar to neonatal NEC, suggesting that lack of EGFR stimulation may play a role in the development of NEC (22). Dvorak *et al.* have shown that EGF supplementation reduces the incidence of NEC in rats, and reduces apoptosis, barrier failure, and hepatic dysfunction (23). Vinter-Jensen *et al.*, investigated the effect of s.c. administered EGF (150 $\mu\text{g}/\text{kg}/12\text{ h}$) in rats, for 1, 2, and 4 wk, and found that EGF induced growth of small intestinal mucosa and muscularis in a time-dependent manner (24). Several case reports of clinical administration of EGF also exist. Sigalet *et al.* administered EGF (100 $\mu\text{g}/\text{kg}/\text{d}$) mixed with enteral feeds for 6 wk to pediatric patients with short bowel syndrome, and reported improved nutrient absorption and increased tolerance to enteral feeds with no adverse effects (25). Sullivan *et al.*, in a prospective, double-blind, randomized controlled study that included eight neonates with NEC, compared the effects of a 6-d continuous i.v. infusion of EGF (100 ng/kg/h) to placebo, and found a positive trophic effect of EGF on the intestinal mucosa (26). Palomino *et al.* examined the efficacy of EGF in the treatment of duodenal ulcers in adults, and found that oral human recombinant EGF (50 mg/mL every 8 h for 6 wk) was effective with no side effects noted (27).

In a recent report, Dvorak *et al.* compared the effect of enteral administration of HB-EGF compared with EGF in protection from NEC in newborn rats (28). The authors concluded that both growth factors could protect rat pups from developing NEC, but suggested that EGF may be effective at more physiologic levels. The basis of that conclusion is not totally clear, because both growth factors in their study had maximal beneficial effects at the same dose (500 ng/mL). There are several difficulties encountered when comparing the results of the Dvorak study with ours. First, Dvorak *et al.* report their growth factor doses in ng/mL rather than in ng or $\mu\text{g}/\text{kg}/\text{dose}$. We dose our rat pups in $\mu\text{g}/\text{kg}/\text{dose}$ because this is directly comparable to the doses pediatric patients receive clinically, and because this allows us to determine the human equivalent dose of HB-EGF using the following formula (29):

$$\text{HED} = \text{animal dose in mg/kg} \times [\text{animal weight in kg} / \text{human weight in kg}]^{0.33}$$

Furthermore, Dvorak *et al.* never state the volume (mL) of the feeds that were administered, or the number of doses that were administered daily, making it impossible to definitively determine the exact amounts of growth factors administered. However, if we assume that they administered 0.1–0.4 mL/feed, and that their newborn rat pups weighed ~0.005 kg, then they delivered ~10–40 $\mu\text{g}/\text{kg}/\text{dose}$ of HB-EGF or EGF in their experiments, which is ~20-fold less HB-EGF than the most efficacious dose of HB-EGF in our hands. In fact, using the NEC injury grading system that we use [as proposed by Caplan *et al.* (15)] we would not see any beneficial effects of HB-EGF at the doses used by Dvorak *et al.* This may be because different injury scoring systems are used in the two studies. Although they do not show any histologic images in their recent paper, previous studies from their laboratory have shown histology (23). What they judge as grade 2 or 3 NEC would not meet the criteria for NEC using our scoring system. What they judge as grade 4 NEC is comparable to what we would judge as grade 2 NEC (the minimal degree of injury required to be considered NEC). We believe that the more severe degrees of injury we are producing in our animal model are more comparable to the clinically relevant, severe structural destruction of the intestines seen in patients afflicted with NEC. Future clinical trials of HB-EGF in humans will be needed to definitively elucidate the doses of HB-EGF that are truly needed to prevent or treat this devastating disease.

Our goal is the clinical use of HB-EGF in the prevention or treatment of NEC. Given the evidence demonstrating the protective effects of HB-EGF against intestinal injury, its use may represent a promising therapeutic strategy for intestinal diseases, including NEC. Because of its ability to enhance the regenerative capacity and/or increase the resistance of the mucosa to injury, HB-EGF has proven to be a strong candidate for human clinical trials for NEC.

Acknowledgments

The authors wish to thank Gregory Young, M.S., Ohio State University Center for Biostatistics, for his helpful comments and his assistance with the statistical analyses.

Supported by Trillium Therapeutics, Inc. (Toronto, Ontario, Canada) (G.E.B., A.R.), NIH RO1 DK074611 (G.E.B.), NIHT32 RR-023260-02 (N.A.Z.), The Samuel J. Roessler Memorial Fellowship (N.A.Z.), and The Firefighters Endowment Fund of Nationwide Children's Hospital (X.Y.).

Abbreviations

EGFR	epidermal growth factor receptor
GMP	good manufacturing process
HB-EGF	heparin-binding EGF-like growth factor
NEC	necrotizing enterocolitis

REFERENCES

1. Schnabl KL, Van Aerde JE, Thomson AB, Clandinin MT. Necrotizing enterocolitis: a multifactorial disease with no cure. *World J Gastroenterol.* 2008; 14:2142–2161. [PubMed: 18407587]
2. Kliegman RM, Fanaroff AA. Necrotizing enterocolitis. *N Engl J Med.* 1984; 310:1093–1103. [PubMed: 6369134]
3. Lee JS, Polin RA. Treatment and prevention of necrotizing enterocolitis. *Semin Neonatol.* 2003; 8:449–459. [PubMed: 15001117]
4. Caplan MS, Jilling T. New concepts in necrotizing enterocolitis. *Curr Opin Pediatr.* 2001; 13:111–115. [PubMed: 11317050]
5. Feng J, El-Assal ON, Besner GE. Heparin-binding EGF-like growth factor (HB-EGF) and necrotizing enterocolitis. *Semin Pediatr Surg.* 2005; 14:167–174. [PubMed: 16084404]
6. Besner G, Higashiyama S, Klagsbrun M. Isolation and characterization of a macrophage-derived heparin-binding growth factor. *Cell Regul.* 1990; 1:811–819. [PubMed: 2088527]
7. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. *Science.* 1991; 251:936–939. [PubMed: 1840698]
8. Junttila TT, Sundvall M, Määttä JA, Elenius K. ErbB4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. *Trends Cardiovasc Med.* 2000; 10:304–310. [PubMed: 11343971]
9. Nishi E, Prat A, Hospital V, Elenius K, Klagsbrun M. N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration. *EMBO J.* 2001; 20:3342–3350. [PubMed: 11432822]
10. Feng J, El-Assal ON, Besner GE. Heparin-binding epidermal growth factor-like growth factor decreases the incidence of necrotizing enterocolitis in neonatal rats. *J Pediatr Surg.* 2006; 41:144–149. [PubMed: 16410124]
11. El-Assal ON, Besner GE. Heparin-binding EGF-like growth factor (HB-EGF) and intestinal ischemia-reperfusion injury. *Semin Pediatr Surg.* 2004; 13:2–10. [PubMed: 14765365]

12. El-Assal ON, Radulescu A, Besner GE. Heparin-binding EGF-like growth factor preserves mesenteric microcirculatory blood flow and protects against intestinal injury in rats subjected to hemorrhagic shock and resuscitation. *Surgery*. 2007; 142:234–242. [PubMed: 17689691]
13. Barlow B, Santulli TV, Heird WC, Pitt J, Blanc WA, Schullinger JN. An experimental study of acute neonatal enterocolitis—the importance of breast milk. *J Pediatr Surg*. 1974; 9:587–595. [PubMed: 4138917]
14. Davis KM, Brigstock DR, Johnson PR, Crissman-Combs MA, McCarthy DW, Downing MT, Besner GE. Production of glycosylated heparin-binding EGF-like growth factor in HeLa cells using vaccinia virus. *Protein Expr Purif*. 1996; 8:57–67. [PubMed: 8812835]
15. Caplan MS, Hedlund E, Adler L, Hsueh W. Role of asphyxia and feeding in a neonatal rat model of necrotizing enterocolitis. *Pediatr Pathol*. 1994; 14:1017–1028. [PubMed: 7855004]
16. Martin AE, Luquette MH, Besner GE. Timing, route, and dose of administration of heparin-binding epidermal growth factor-like growth factor in protection against intestinal ischemia-reperfusion injury. *J Pediatr Surg*. 2005; 40:1741–1747. [PubMed: 16291163]
17. Michalsky MP, Lara-Marquez M, Chun L, Besner GE. Heparin-binding EGF-like growth factor is present in human amniotic fluid and breast milk. *J Pediatr Surg*. 2002; 37:1–6. [PubMed: 11781977]
18. Feng J, Mehta VB, El-Assal ON, Wu D, Besner GE. Tissue distribution and plasma clearance of heparin-binding EGF-like growth factor (HB-EGF) in adult and newborn rats. *Peptides*. 2006; 27:1589–1596. [PubMed: 16364500]
19. Shin CE, Falcone RA Jr, Stuart L, Erwin CR, Warner BW. Diminished growth factor levels in infants with necrotizing enterocolitis. *J Pediatr Surg*. 2000; 35:173–176. [PubMed: 10693661]
20. Warner BB, Ryan AL, Seeger K, Leonard AC, Erwin CR, Warner BW. Ontogeny of salivary epidermal growth factor and necrotizing enterocolitis. *J Pediatr*. 2007; 150:358–363. [PubMed: 17382110]
21. Warner BW, Warner BB. Role of epidermal growth factor in the pathogenesis of neonatal necrotizing enterocolitis. *Semin Pediatr Surg*. 2005; 14:175–180. [PubMed: 16084405]
22. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. *Nature*. 1995; 376:337–341. [PubMed: 7630400]
23. Dvorak B, Halpern MD, Holubec H, Williams CS, McWilliam DL, Dominguez JA, Stepankova R, Payne CM, McCuskey RS. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. *Am J Physiol Gastrointest Liver Physiol*. 2002; 282:G156–G164. [PubMed: 11751169]
24. Vinter-Jensen L, Duch BU, Petersen JA, Ryslev A, Gregersen H. Systemic treatment with epidermal growth factor in the rat. Biomechanical properties of the growing small intestine. *Regul Pept*. 1996; 61:135–142. [PubMed: 8852816]
25. Sigalet DL, Martin GR, Butzner JD, Buret A, Meddings JB. A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome. *J Pediatr Surg*. 2005; 40:763–768. [PubMed: 15937810]
26. Sullivan PB, Lewindon PJ, Cheng C, Lenahan PF, Kuo BS, Haskins JR, Goodlad RA, Wright NA, de la Iglesia FA. Intestinal mucosa remodeling by recombinant human epidermal growth factor in neonates with severe necrotizing enterocolitis. *J Pediatr Surg*. 2007; 42:462–469. [PubMed: 17336181]
27. Palomino A, Hernández-Bernal F, Haedo W, Franco S, Más JA, Fernández JA, Soto G, Alonso A, González T, López-Saura P. A multicenter, randomized, double-blind clinical trial examining the effect of oral human recombinant epidermal growth factor on the healing of duodenal ulcers. *Scand J Gastroenterol*. 2000; 35:1016–1022. [PubMed: 11099053]
28. Dvorak B, Khailova L, Clark JA, Molla Hosseini D, Arganbright KM, Reynolds CA, Halpern MD. Comparison of epidermal growth factor and heparin-binding epidermal growth factor–like growth factor for prevention of experimental necrotizing enterocolitis. *J Pediatr Gastroenterol Nutr*. 2008; 47:11–18. [PubMed: 18607263]
29. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services, Food

and Drug Administration, Center for Drug Evaluation; 2005. Available at: <http://www.fda.gov/CDER/GUIDANCE/5541fnl.htm>




Figure 1. Histologic injury score in rat pups subjected to experimental NEC. Shown are representative H&E-stained sections showing (A) normal intestine, (B) Grade 1, epithelial cell lifting or separation, (C) Grade 2, sloughing of epithelial cells to the mid villous level, (D) Grade 3, necrosis of the entire villus, and (E) Grade 4, transmural necrosis. Magnification $\times 40$.




Figure 2. HB-EGF dosing interval. (A) NEC Score. The effect of HB-EGF (800 $\mu\text{g}/\text{kg}/\text{dose}$) added to feeds one (QD), two (BID), three (TID), four (QID), or six (HID) times a day on the development of NEC is shown. Each dot represents a single rat pup exposed to NEC, and the NEC score for each pup is shown. (B) Incidence of NEC. The percent of animals with NEC at each dosing interval is shown. * $p < 0.05$ compared with the non-HB-EGF-treated control group. N/A, no addition of HB-EGF to feeds. Grade 2 NEC, ■; grade 3 NEC, ▒; grade 4 NEC, □.




Figure 3.

Comparison of *E. coli*- and *P. pastoris*-derived HB-EGF in prevention of NEC. (A) NEC Score. Recombinant HB-EGF derived from *E. coli* or *P. pastoris* was tested at doses of 600, 800, or 1000 $\mu\text{g}/\text{kg}/\text{dose}$, added to feeds either QID or HID. Each dot represents a single rat pup exposed to NEC, and the NEC score for each pup is shown. No addition of HB-EGF, ●; *E. coli*-derived HB-EGF HID, ●; *P. pastoris*-derived HB-EGF HID, ⊗; *P. pastoris*-derived HB-EGF QID, ○. (B) Incidence of NEC. The percent of animals with NEC in pups that were treated with *E. coli*- or *P. pastoris*-derived HB-EGF is shown. No addition of HB-EGF, ■; *E. coli*-derived HB-EGF HID, ▣; *P. pastoris*-derived HB-EGF HID, ▤; *P. pastoris*-derived HB-EGF QID, □. * $p < 0.05$ compared with the non-HB-EGF-treated control group; §, not significant; N/A, no addition of HB-EGF.




Figure 4.

Comparison of HB-EGF and EGF in prevention of NEC. (A) NEC Scores. Either equal molar (800 $\mu\text{g}/\text{kg}/\text{dose}$ HB-EGF versus 570 $\mu\text{g}/\text{kg}/\text{dose}$ EGF) or equal mass (800 $\mu\text{g}/\text{kg}/\text{dose}$ HB-EGF versus 800 $\mu\text{g}/\text{kg}/\text{dose}$ EGF) amounts of HB-EGF and EGF were compared in their ability to prevent NEC. Each dot represents a single rat pup exposed to experimental NEC, and the NEC score for each pup is shown. (B) Incidence of NEC. The percent of animals with NEC in pups that received either equal molar or equal mass amounts of HB-EGF or EGF is shown. * $p < 0.05$ compared with the non-growth factor-treated control group; §, not significant; N/A, no addition of HB-EGF to feeds. Grade 2 NEC, ■; grade 3 NEC, ▒.




Figure 5.

Comparison of prophylactic and therapeutic administration of HB-EGF. (A) NEC Scores. The effect of HB-EGF ($800 \mu\text{g}/\text{kg}/\text{dose}$) added to feeds starting with the first feed at 2 h after birth, or at 12, 24, 48, or 72 h after birth is shown. Each dot represents a single rat pup exposed to experimental NEC, and the NEC score for each pup is shown. (B) Incidence of NEC. The percent of animals with NEC in pups that received HB-EGF ($800 \mu\text{g}/\text{kg}/\text{dose}$) starting 2, 12, 24, 48, or 72 h after birth is shown. * $p < 0.05$ compared with the non-HB-EGF-treated control group; N/A, no addition of HB-EGF. Grade 2 NEC, ■; grade 3 NEC, ■.